Club cells are the primary source of pIgR in small airways

Jessica B. Blackburn¹,², Jacob A. Schaff¹,², Sergey Gutor², Rui-Hong Du², David Nichols², Taylor Sherrill², Austin J. Gutierrez³, Matthew K. Xin², Nancy Wickersham², Yong Zhang⁴, Michael J. Holtzman⁴, Lorraine B Ware², Jae Woo Lee⁵, Nicholas E. Banovich³, Jonathan A. Kropski¹,²,⁶, Vasiliy V. Polosukhin¹, Timothy S. Blackwell¹,²,⁶, and Bradley W. Richmond¹,²,⁶*

¹Department of Veterans Affairs Medical Center, Nashville, TN.
²Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN.
³Translational Genomics Research Institute, Phoenix, AZ
⁴Division of Pulmonary and Critical Care Medicine, Washington University-St. Louis, St. Louis, MO
⁵Department of Anesthesia and Perioperative Care, University of California-San Francisco, San Francisco, California
⁶Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN

*To whom correspondence should be addressed:
Bradley W. Richmond, M.D., Ph.D.
Division of Allergy, Pulmonary and Critical Care Medicine
Vanderbilt University School of Medicine, T-1218 MCN
Nashville, TN 37232-2650

Email: bradley.richmond@vumc.org; Phone: 615-875-7583; Fax: 877-992-6251

Conflict of interest: The authors have declared that no conflict of interest exists.
Abstract

Background: Loss of secretory immunoglobulin A (SIgA) is common in COPD small airways and likely contributes to disease progression. We hypothesized loss of SIgA results from reduced numbers of cells expressing pIgR, a chaperone protein needed for SIgA transcytosis, in the COPD small airway epithelium.

Methods: pIgR-expressing cells were defined and quantified at single-cell resolution in human airways using RNA in-situ hybridization, immunostaining, and single-cell RNA sequencing. Complementary studies in mice utilized immunostaining, primary murine tracheal epithelial cell (MTEC) culture, and transgenic mice with club or ciliated cell-specific knockout of pIgR. SIgA degradation by human neutrophil elastase or secreted bacterial proteases from non-typeable *Haemophilus influenzae* (NTHi) was evaluated in vitro.

Results: Club cells are the predominant cell type responsible for pIgR expression in human and murine airways, but neither loss of pIgR-expressing club cells or reduced pIgR expression in individual cells fully explains loss of SIgA in the airways in patients with advanced COPD. In contrast, we found that neutrophil elastase and NTHi-secreted proteases degrade SIgA in vitro.

Interpretation: Club cells are the dominant cell type responsible for pIgR expression and thus play a key role in maintaining the secretory IgA immunobarrier. However, neither a loss of club cells or reduced pIgR expression within individual cells fully accounts for loss of SIgA in COPD.
Key Messages:

What is the key question? This study addresses whether loss of S1gA in the small airways of COPD patients is due to reduced numbers of pIgR-expressing cells or reduced pIgR expression per cell.

What is the bottom line? pIgR is expressed primarily by club cells in human and murine airways, but neither loss of these cells or reduced pIgR expression per cell fully explains loss of S1gA in COPD small airways.

Why read on? S1gA levels on the surface of small airways are determined by rates of production, transcytosis across the airway epithelium, and degradation. This study suggests pIgR-independent defects in S1gA transcytosis or S1gA degradation may be more important determinants of airway S1gA levels than previously appreciated.
Introduction

Throughout life the lungs are bombarded by inhaled particulates, microorganisms, and endogenous bacteria aspirated from the upper respiratory tract (1). Many such irritants are deposited on the surface of small airways where bulk airflow ceases and gas transfer proceeds through diffusion (2). To facilitate homeostasis, the small airway epithelium maintains a multifaceted defense system that protects against microbial invasion while limiting potentially injurious inflammatory responses (3, 4). A key component of this system is secretory immunoglobulin A (SIgA) which lines the lumen of small airways and other mucosal surfaces (5-9). SIgA opsonizes and agglutinates microorganisms and non-infectious irritants to facilitate their clearance through the mucociliary escalator (6). Through a process known as immune exclusion, SIgA limits inflammation by masking pathogen-associated molecular patterns (PAMPs) and preventing them from activating inflammatory signaling cascades in the airway epithelium (6).

In 2001, Pilette and colleagues made the seminal discovery of reduced secretory component (SC, a component of SIgA) in the airways of patients with chronic obstructive pulmonary disease (COPD) (10), a common and often fatal lung disease associated with cigarette smoking (11). Further, they reported that loss of SC is associated with increased neutrophilic inflammation (10). We extended these findings to show that loss of SIgA correlates with increased bacterial invasion into small airway walls, COPD-like innate and adaptive immune activation, and small airway wall fibrosis in small airways from patients with COPD (12, 13). Further, we reported that SIgA-deficient mice spontaneously develop progressive lung inflammation, small airway wall thickening, and emphysema similar to patients with COPD (14-16), suggesting loss of SIgA immunobarrier directly contributes to COPD pathogenesis.
Regulation of SIgA on mucosal surfaces is a complex process involving multiple cell types and processes (5). Dimeric IgA (dIgA) is made by plasma cells which reside beneath the airway epithelium in the lamina propria. To cross the airway epithelium to the luminal surface, dIgA covalently binds to the polymeric immunoglobulin receptor (pIgR) on the basolateral surface of the airway epithelium. pIgR/dIgA complexes are endocytosed and transported to the apical surface through vesicular trafficking (17). At the apical surface an endoproteolytic cleavage event releases dIgA and the extracellular portion of pIgR called the secretory component (SC) to form SIgA. At the airway surface, SIgA is susceptible to cleavage by host and bacterial proteases (18-24). Thus, the amount of SIgA present on the airway surface depends upon rates of production, transport, and degradation. To better understand regulation of the SIgA barrier in the lungs, we defined cell type-specific expression of pIgR in human and murine small airways using complementary in situ, in vitro, and in vivo approaches. We then evaluated potential mechanisms accounting for loss of SIgA in small airways of patients with COPD.

**Results**

pIgR is primarily expressed by club cells in human airways.

Club and ciliated cells comprise the majority of epithelial cells lining human small (< 2 mm) airways (25). To determine which of these cell types express pIgR, we performed RNA in situ hybridization (RNA-ISH) for PIGR, SCGB1A1 (a marker of club cells), and FOXJ1 (a marker of ciliated cells) in small airways from deceased lung donors without known respiratory disease whose lungs were rejected for transplantation (e.g. control subjects). Immunofluorescence microscopy showed areas of co-localization between PIGR and SCGB1A1.
but minimal overlap between PIGR and FOXJ1 (figure 1A). Using HALO image analysis software (Indica Labs) we quantified each probe 3 μm around DAPI-stained nuclei in segmented airway epithelial cells (online supplemental figure 1), allowing us to define FOXJ1+ and SCGB1A1+ cells with minimal overlap between markers (figure 1B, first two panels). Using this technique, we observed higher probe expression for PIGR in SCGB1A1+ club cells compared to FOXJ1+ ciliated cells (figure 1B, right panel). Further, by using 2 different markers of club cells (SCGB1A1 and SCGB3A2) (26), we were able to account for 83% of PIGR+ cells (figure 1C,D) suggesting these cells are the dominant cell type responsible for PIGR expression in small airways. These findings were confirmed at the protein level by immunostaining in small and large airways from control patients, which showed pIgR localized in cells that contained Scgb1a1 but not Fox1 (figure 1E).

To gain a more comprehensive understanding of the pattern of PIGR expression across the respiratory epithelium, we performed single-cell RNA sequencing (scRNA-seq) of distal portions of explanted lungs from COPD patients (n = 11) and analyzed these samples alongside our previously published scRNA-seq data from analogous regions of lung from non-diseased controls (27). All samples were jointly normalized and scaled prior to graph-based clustering and manual annotation using canonical markers as previously described (27) (figure 2A-C, online supplemental figure 2). Graph-based clustering yielded three distinct populations of cells bearing markers typical of club cells which could be differentiated by expression of SCGB1A1, SCGB3A2, or both markers. Similar to what was observed by RNA in situ hybridization and immunostaining, PIGR expression was highest in these club cell populations in both COPD patients and non-diseased controls (figure 2D). The level of expression was similar
between COPD and control samples except in ciliated cells and SCGB1A1+/SCGB3A2+ club cells, where expression was higher in COPD samples (figure 2D).

**pIgR is primarily expressed by club cells in murine airways.**

Similar to human airways, we found pIgR co-localized with Scgb1a1 by immunostaining but not the ciliated cell marker acetylated α-tubulin in wild-type (WT) C57Bl6/J mice (figure 3A). Additionally, we isolated tracheal epithelial cells from WT mice and treated them with DAP-T, an inhibitor of club cell maturation (28), during terminal differentiation in air-liquid interface (ALI) culture (figure 3A). DAP-T markedly reduced pIgR expression in whole-cell lysates (figure 3C,D), consistent with the idea that club cells are the dominant cell type responsible for pIgR expression. Levels of acetylated α-tubulin did not differ between DAP-T and control samples, suggesting loss of pIgR was not due to loss of ciliated cells (figure 3C). Since ciliated cells outnumber club cells in the distal airways of humans and mice (25), we speculated that even low amounts of pIgR expression in ciliated cells may be relevant to SIgA transport in the distal airways in vivo. To investigate this further, we generated a mouse model for conditional pIgR deletion by placing loxP sites upstream of exon 3 and downstream of exon 11 of the pIgR gene, which includes the binding sites for dIgA (online supplemental figure 3A). The coding regions of green fluorescent protein (GFP) were introduced upstream and downstream of the two loxP sites, such that Cre recombinase-mediated excision of exons 3-11 results in GFP expression. pIgRfl/fl mice were bred to Scgb1a1.CreERT2 mice (29) to generate tamoxifen-inducible deletion of pIgR in club cells (pIgRΔclub mice) and FoxJ1.Cre mice (30) to generate constitutive deletion of pIgR in ciliated cells (pIgRΔciliated mice) (online supplemental...
**figure 3B**. In plgRΔclub mice, Cre recombinase was activated by placing mice on tamoxifen chow every other week (to minimize toxicity) for 3 months (**online supplemental figure 3C**). 

plgRΔciliated and plgRΔclub mice were evaluated by immunofluorescence to assess plgR expression and GFP to confirm Cre-mediated recombination. Cre− littermate controls from both lines showed no expression of GFP (**figure 4A,B, left panels**). We observed weak expression of GFP in plgRΔciliated mice (**figure 4A, right panel**), suggesting low levels of plgR expression in FoxJ1+ ciliated cells. However, despite plgR deletion from ciliated cells in these mice, many airway epithelial cells continued to express plgR (**figure 4A, right panel, white arrows**). In contrast, we observed very few plgR-expressing cells in plgRΔclub mice (**figure 4B, right panel**) and GFP expression was much more robust in plgRΔclub mice than plgRΔciliated mice (**online supplemental figure 4A,B**). We also performed western blotting for plgR in whole-lung lysates from plgRΔciliated and plgRΔclub mice to measure global plgR expression. In plgRΔciliated mice there was no difference in plgR levels between Cre+ and Cre− littermate controls (**online supplemental figure 4C,D**). In contrast, in plgRΔclub mice there was a marked reduction of full length plgR in Cre+ mice compared to littermate control and plgRΔciliated mice.

We previously noted mice with a global loss of plgR (plgR−/− mice) lack SIgA in small airways and spontaneously develop emphysema by 6 months of age (14). To evaluate the importance of ciliated cell-derived plgR for prevention of emphysema we measured mean linear intercept (Lm, a morphometric measure of emphysema) in 6-month-old plgRΔciliated mice, Cre− littermate controls, and syngeneic WT mice. We found no difference in Lm between these groups (**figure 4E,F**), suggesting SIgA transport by non-ciliated cell types is sufficient to maintain homeostasis in the distal lungs. Taken together, these in vivo studies support the idea that club cells are the dominant cell type responsible for epithelial transport of SIgA.
Changes in club cell numbers do not explain loss of SIgA in COPD airways.

Having established club cells as the dominant cell type responsible for pIgR expression, we questioned whether loss of these cells contributes to reduced SIgA in COPD airways. Using RNA-ISH, we quantified $SCGB1A1^+$ and $SCGB3A2^+$ cells in small airways and found a similar proportion of club cells between COPD and control subjects, although there was a shift towards reduced numbers of $SCGB3A2^+$ club cells (figure 5A). To test whether there were regional differences in club cells in COPD patients that particularly impacted airways with SIgA deficiency (SIgA−) as compared to airways with an intact SIgA barrier (SIgA+), we performed immunostaining for SIgA as previously described (13) and RNA in situ hybridization for $SCGB1A1$ and $SCGB3A2$ (figure 5B). Consistent with prior data (13), 82% of small airways analyzed from this cohort of patients with severe COPD were SIgA-deficient. However, we found no difference in numbers of $SCGB1A1^+$ or $SCGB3A2^+$ cells between SIgA+ and SIgA− airways (figure 5C) indicating loss of club cells does not explain SIgA deficiency in small airways of patients with advanced COPD.

In addition to loss of club cells, another possibility to explain the impaired mucosal immune barrier in SIgA− airways could be reduction of pIgR expression in individual cells. Therefore, we performed immunostaining for pIgR in sections of COPD lungs with SIgA− and SIgA+ airways ($n = 8$ patients, 101 small airways examined). We found no difference in the amount of pIgR expressed per cell or percentage of pIgR-expressing cells among airway epithelial cells from SIgA+ and SIgA− airways (figure 5D-F), suggesting factors other than level of pIgR expression must contribute to the reduction in surface SIgA in individual airways from patients with advanced COPD.
Since previous studies have indicated SIgA may be degraded by bacterial or host proteases (18-24), we evaluated whether SIgA is degraded by non-typeable Haemophilus influenzae (NTHi), the most common bacterium isolated from the lungs of COPD patients (31), or sputum-derived human neutrophil elastase (HNE) in vitro. We incubated SIgA derived from human colostrum with conditioned media from NTHi 1479 (a clinical isolate from a COPD patient) or with HNE and performed western blots for the IgA heavy chain and the secretory component. We found that conditioned media from NTHi cleaved the IgA heavy chain but not secretory component of SIgA, consistent with IgA protease activity (figure 6A-C). In contrast, HNE degraded the IgA heavy chain and secretory component, forming several lower molecular weight degradatory products (figure 6D-F). These in vitro data support the idea that bacterial or host proteases known to be present in the airway lumen in COPD may contribute to loss of SIgA in COPD.

Discussion

Loss of SIgA is common in COPD small airways and is an established driver of COPD progression in animal models (10, 12-16). However, the mechanism of SIgA remains poorly understood, particularly in small airways. Here we show that club cells are the predominate source of PIGR/pIgR expression in human and murine small airways and thus define a new niche for these cells in maintenance of the SIgA immunobarrier. Further, we show that SIgA+ and SIgA− small airways from patients with advanced COPD have similar numbers of pIgR-expressing cells and pIgR expression per cell, suggesting factors other than pIgR expression such as altered pIgR/dIgA trafficking or SIgA degradation contribute to loss of SIgA on the surface of individual small airways from patients with advanced COPD.
The finding that club cells are the predominant source of pIgR expression is consistent with published human and murine scRNA-seq datasets (27, 32-36) and with the known role of club cells in immune defense and airway homeostasis (34). Although ciliated cells also produce low levels of pIgR and are more numerous than secretory cells in distal airways, we did not observe lung pathology in mice with ciliated cell-specific deletion of pIgR. This finding suggests that club cells play a dominant role in maintaining the SIgA immunobarrier. Interestingly, we found a shift towards reduced SCGB3A2⁺ club cells in COPD airways consistent with other studies showing a reduction in SCGB3A2 gene expression in COPD (37, 38). This finding merits additional investigation.

Here we found that loss of SIgA was independent of the number of pIgR-expressing cells or pIgR expression per cell in advanced COPD lungs. We propose two potential explanations for this observation. First, SIgA was previously found to be reduced in airways with goblet cell hyperplasia or squamous metaplasia (13) and it is possible that in these abnormal cell types there are functional defects in pIgR or pIgR-independent defects in pIgR/dIgA transcytosis. Future in vitro experiments using COPD-relevant models of abnormal epithelial differentiation such as that recently reported by Rao and colleagues (39) would be helpful in examining this further. Second, loss of SIgA in COPD airways could result from degradation by bacterial or host proteases. We found that the IgA heavy chain was degraded by NTHi 1479, a clinical isolate of the most common bacterium isolated from the lungs of COPD patients during exacerbations (31). A variety of bacteria have been shown to degrade SIgA (18, 19, 22-24) and it is conceivable that SIgA-degrading bacteria are overrepresented in COPD patients during stable and/or exacerbated periods (40, 41). Additionally, we found that HNE is capable of degrading the IgA heavy chain and secretory component. Neutrophils are recruited to SIgA-deficient airways in mice (14, 15),
and thus degradation by host proteases may further reduce SIgA levels once deficiency has been established. Future studies examining SIgA fragmentation patterns in bronchoalveolar lavage fluid samples could prove useful for determining the specific proteases degrading SIgA.

There are several important limitations to our study. Many patients in our scRNA-seq control cohort were light smokers whereas all patients in the COPD cohort were former smokers which could have affected PIGR/pIgR expression and/or club cell number. Additionally, since control samples were taken from diseased lung donors whose lungs were declined for transplantation, it is likely that at least some of these donors had acute lung pathology such as pulmonary hemorrhage or pneumonia which also could have influenced pIgR expression. While also subject to biases, future studies involving unaffected tissue from lung nodule/cancer resections would be complementary if matched to COPD samples by age and smoking status.

In summary, our study suggests that club cells are uniquely responsible for maintaining the SIgA immunobARRIER, and that loss of SIgA in COPD is in part pIgR-independent. These data should prompt additional study into other factors that might influence SIgA levels in COPD small airways.
Funding

This work was supported by IK2BX003841 from the Department of Veterans Affairs (B.W.R.), T32 5HL094296 (J.B.B., T.S.B. PI), NIH/NHLB1 K08 HL138008 (B.W.R.), l01BX002378 from the Department of Veterans Affairs (T.S.B.), NIH/NIAID R01 AI130591 and NIH/NHLBI R35 HL145242 (M.J.H.), NIH HL126176 (L.B.W.), NIH/NHLBI R01HL145372 (J.A.K./N.E.B.), K08HL130595 (J.A.K.), and the Doris Duke Charitable Foundation (J.A.K.).

Acknowledgements

The authors would like to thank Angela Jones and Neha Joshi in the Vanderbilt Technologies for Advanced Genomics (VANTAGE) Core for assistance with scRNA-seq. Additionally, the authors would like to thank the Vanderbilt Lung Transplant Team and the Vanderbilt Department of Surgical Pathology for assistance obtaining lung explants.
Methods

Human samples. The explanted lungs of COPD patients were obtained after informed consent according to Institutional Review Board (IRB)-approved protocols from Vanderbilt University Medical Center and Norton Thoracic Institute (Vanderbilt IRB #060165, 171657; Norton IRB #20181836). Control samples were obtained from deceased organ donors and were exempt from IRB review. Demographic and clinical information for human samples is provided in Supplemental Table 1. Demographic and clinical information for control lungs used for scRNA-seq have been published previously but are included here for reference (27).

Mouse models. All mouse experiments were performed according to a protocol approved by the Institutional Animal Care and Use (IACUC) Committee at Vanderbilt University Medical Center. Scgb1a1.CreERT2 mice were generated in the lab of Dr. Brigid Hogan (29) and were obtained from the Jackson Laboratory (catalog #16225). Transgene activation was induced with tamoxifen citrate-impregnated (400 mg/kg) chow (Envigo, catalog no. 130860) as described in the main text. FoxJ1.Cre mice were originally developed in the lab of Dr. Michael Holtzman (30) and were a gift from the developers. The flox-pIgR mouse line was developed with Ingenious Targeting Labs (Ronkonkoma, NY). A targeting vector was generated in which loxP sites were inserted upstream of PIGR exon 3 and downstream of exon 11, which includes the binding domains for pIgR (5). The coding regions of the GFP gene were introduced upstream and downstream of the two loxP sites, such that excision of exons 3-11 via Cre-recombinase results in GFP expression. Selection was achieved by introduction of a neomycin selection cassette flanked by FRT sites downstream of exon 11. This construct was electroporated into C57BL/6J FLP embryonic stem cells which were screened for neomycin resistance. Positive cells were injected into BALB/c blastocysts and then surgically inserted into pseudo-pregnant...
females. Resulting chimeras with a high percentage of black coat color were mated to C56BL/6J mice to generate germline neo-deleted mice, which was confirmed by Southern blot. A map of the targeting vector is included as **Supplemental Fig. 3.** C57BL/6J mice were purchased from the Jackson Laboratory (catalog #000664) or bred in-house after originally being purchased from the Jackson Laboratory. Approximately equal numbers of male and female mice 2 months of age or older were used in all experiments.

**Single-cell RNA sequencing.**

*Tissue Processing.* Biopsies from each lung sample were digested in an enzymatic cocktail (Miltenyi Multi-Tissue Dissociation Kit or collagenase I/dispase II 1 μg/ml tissue) using a gentleMACS Octo Dissociator (Miltenyi, Inc). Tissue lysates were serially filtered through sterile gauze, 100 μm, and 40 μm sterile filters (Fisher). Single cell suspensions then underwent cell sorting using serial columns (Miltenyi Microbeads, CD235a, CD45) or FACS. At VUMC, CD45− and CD45+ populations mixed 2-3:1 were used as input for generation of scRNA-seq libraries. At TGen, Calcien-AM was used to stain live cells and 10,000-15,000 total live cells were sorted directly into the 10X reaction buffer and transferred immediately to the 10X 5’ chip A (10X Genomics).

*scRNA-seq library preparation and next-generation sequencing.* scRNA-seq libraries were generated using the 10X Chromium platform 5’ library preparation kits (10X Genomics) targeting 10,000 cells per sample. Next generation sequencing was performed on an Illumina Novaseq 6000 using Illumina S1 flow cell with paired end reads. Reads with Phred scores <30 were filtered out and 10X Genomics CellRanger v3 (for VU_COPD_29 and VU_COPD_34) or v5.0.0 (all other samples) was used to align reads to the GRCh38 reference genome.
scRNA-seq analysis. Post-alignment analysis was performed using the Seurat v4.0.1 package in R. Quality control filtering was performed using detected genes (minimum 750) and mitochondrial reads percent (minimum 0%, maximum 15%). All data (COPD, IPF, and control samples) were jointly normalized and scaled using the SCTransform function in Seurat (50). Epithelial (EPCAM⁺), stromal (EPCAM⁻/PTPRC⁻) and immune (PTPRC⁺) cells were then extracted into independent objects which underwent SCT-Integration (42) followed by principal component analysis, recursive clustering, UMAP embedding, and cell-type annotation. Clusters comprised of non-physiologic marker combinations (i.e., PTPRC⁺/EPCAM⁺ cells) were presumed doublets and excluded from further downstream analysis. Cell-type specific differentiation expression analysis was performed as previously described(27). For this dataset, only EPCAM⁺ epithelial populations were examined. The code used to generate the dataset is available at https://www.github.com/kropskilab/copd/. Gene Expression Omnibus (GEO) repository number pending.

RNA in situ hybridization. RNA in situ hybridization was performed on formalin-fixed, paraffin-embedded (FFPE) tissue using the RNAscope platform (ACDBio, manual multiplex kit V2). Probes used include PIGR-C1, SCGB3A2-C2, SCGB1A1-C3, and FOXJ1-C2. Positive and negative control probes were also used to validate RNA integrity and signal specificity. TSA Plus fluorophores (fluorescein, Cy3, and Cy5) were purchased from Akoya Biosciences. Fluorophores were used at concentrations between 1:750 and 1:1500. Slides were imaged on a Nikon spinning disk confocal microscope (Yokogawa CSU-X1 spinning disk head, Andor DU-897 EMCCD, high-speed piezo [z] stage and a four-line high-power solid state laser launch) or on a Keyence BZ-710.
HALO analysis. Quantification of RNAscope images and pIgR immunostaining was performed using HALO image analysis software version 1-3 with the FISH-IF module (Indica Labs). Only cells within airway epithelia were quantified. DAPI was used to identify individual cells and a cell radius of 3 μm outside of the DAPI stained area was set to identify probes/signal within each cell while minimizing probe/signal spill over from adjacent cells or signal on the apical surface of the epithelium. Cells were segmented aggressively to avoid cell overlap. Minimum threshold for probe intensity for RNA-ISH or staining intensity for IF and contrast threshold was determined for each set of staining by adjusting settings for best mask fitting using real-time tuning to eliminate nonspecific signal using irrelevant areas outside of the airway epithelium as baseline for zero expression/staining. Probes were also segmented aggressively.

Immunostaining. For FFPE tissue, 5 μM sections were deparaffinized then antigen retrieval was performed using citrate buffer at pH 6. For ALI culture stains membranes were fixed in 4% PFA for 15 minutes and stored in PBS at 4°C until use. Samples were then permeabilized with 0.1% Triton prior to blocking with 1% BSA in PBS. Antibodies were incubated overnight at 4°C. Antibodies used were: pIgR (rabbit anti-human, Sigma, HPA012012, 1:1000 amplified), pIgR (goat anti-mouse, R&D systems, AF2800, 1:100 amplified), FoxJ1 (rabbit anti-human, Sigma, HPA005714, 1:500 amplified), acetylated α-tubulin (mouse anti-mammal, Santa Cruz, sc-23950, 1:100) Scgb1a1 (rat anti-human, R&D systems, MAB4218, 1:50 amplified), Scgb1a1 (rabbit anti-mouse, Abcam, ab40873, 1:1000), GFP (chicken anti-GFP, Aves labs, GFP-1010,1:250), and IgA (rabbit anti-human, Dako, A0262, 1:75). For amplified targets the appropriate HRP-conjugated secondary was then incubated at 1:250 in PBS for 45 minutes-1hr followed by TSA fluorophore treatment (Perkin-Elmer). For unamplified targets appropriate Cy3 or FITC labeled secondary antibodies were used at 1:100. Images were taken on a Nikon spinning disk confocal.
microscope (Yokogawa CSU-X1 spinning disk head, Andor DU-897 EMCCD, high-speed piezo [z] stage and a four-line high-power solid state laser launch) or on a Keyence BZ-710.

**SIgA assessment.** Airways were binned into SIgA⁺ and SIgA⁻ based on fluorescent signal of IgA on the luminal surface as previously described (13).

**Western blots.** Whole-tissue lysates were prepared from flash-frozen lung tissue (for Flox-pIgR experiments) or whole-cell lysates (for MTEC experiment) using RIPA buffer supplemented with protease inhibitors. Protein concentrations were determined by bicinchoninic acid (BCA) assay and 15 µg of protein (or 8 µg of SIgA for *in vitro* degradation assays) was separated on a 10% acrylamide gel and transferred to a nitrocellulose membrane. Immunoblotting was performed using antibodies against murine pIgR (goat anti-mouse, R&D catalog no. AF2800, 1:1000), β-actin (mouse anti-multispecies, Sigma A5316, 1:40,000), α-tubulin (1:1000), IgA heavy chain (rabbit anti-human, Dako, A0262 1:1000) and secretory component/pIgR (goat anti-human, R&D AF2717, 1:500) followed by detection with fluorescent secondary antibodies (1:10,000) using the Odyssey Imaging System (Li-Cor). Densitometry was performed using Image Studio, and standardized to β-actin.

**Cell culture.**

*Murine tracheal epithelial cell (MTEC) isolation, culture, and DAP-T treatment.* MTECs were isolated and cultured as described by You and colleagues (43). Briefly, adult C57BL/6J mice were euthanized and tracheas isolated and split longitudinally to expose the lumen. Tracheas were placed in 1.5 mg/ml Pronase E in Ham’s/F12 containing antibiotics and incubated overnight at 4°C. Cells were dislodged from the tracheas by gentle agitation in Ham’s/F12 containing 10% fetal bovine serum (FBS), collected by centrifugation at 500 x g, and resuspended in MTEC basic medium (43) containing 10% FBS. Cells were then plated onto a
Primaria tissue culture dish (Corning, catalog #353801) for 3–4 hr. at 37°C with 5% CO₂ to adhere contaminating fibroblasts. Non-adherent cells were then collected and resuspended in MTEC complete media (43) and seeded at a density of 0.8 x 10⁵ onto Transwell inserts (Corning, catalog #3470) pre-coated with 0.05 mg/ml rat tail Type 1 collagen. After cells reached confluence (~Day +10), they were lifted to generate air-liquid interface (ALI) cultures with MTEC 2% NuSerum/RA medium (43) added only to the lower chamber. For the DAP-T experiment, 10 μM DAP-T (Abcam, catalog #120633) was added to media in the basolateral chamber for 14 days of ALI culture. Control wells were treated with diluent (DMSO) only.

**In vitro SIgA degradation experiments.** For the NTHi degradation experiment, NTHi strain 1479 (a gift from Dr. Brahm Segal, University of Buffalo) was grown overnight at 37°C on chocolate agar plates (Hardy Diagnostics). A single colony was used to inoculate 20 ml of brain-heart infusion (BHI) media (Sigma-Aldrich) supplemental with 10 μg/ml NAD and 10 μg/ml Hemin (both from Sigma-Aldrich). The culture was incubated for 4 hours at 36°C with constant shaking and then used to inoculate an additional 200 ml of liquid media. After another 4 hours of growth, bacteria were pelleted and the conditioned media filtered using a 0.22 μm PES filter. This media (25uL) was incubated with 25 μg (1ug/uL, 25uL) SIgA from human colostrum (Athens Research and Technology, 16-13-090701). For the human neutrophil elastase (HNE) experiment, 25 μg of SIgA was incubated with 10 μg sputum-derived human neutrophil elastase (1 ug/uL in 0.05 M NaOAc pH 5 containing 0.1 M NaCl, Elastin Products Company, SE563GI) with or without a protease inhibitor (Sigma, P8340 1:100).

**Statistics and graphing.** Mice were randomly assigned to study groups and all animals were included in each analysis. Results are presented as mean ± standard error of the mean unless
otherwise noted. GraphPad Prism 9 was used for statistical testing and graphing. Type of test and $p$ value are noted in each figure legend.
Figure Legends

Figure 1. PIGR/pIgR is primarily expressed by secretory cells in human lung sections. (A) RNA in situ hybridization for PIGR (red), the secretory cell marker SCGB1A1 (green, left panel), the ciliated cell marker FOXJ1 (green, right panel), and DAPI (gray) in small airways from deceased lung donors without chronic respiratory disease. Scale bar = 50 μm. (B) FOXJ1, SCGB1A1, and PIGR expression (probe counts) in cells defined as SCGB1A1* and FOXJ1*, anything under 10 probes per cell was considered background or overlap from adjacent cells. Error bars represent median values and 95% confidence interval. * = p < 0.0001 (Mann-Whitney test). (C) RNA in situ hybridization showing heterogenous expression of PIGR (blue), SCGB1A1 (green), and SCGB3A2 (red) and the combination of each marker in a small airway from a control patient. Scale bar = 50 μm. (D) Percentage of cells expressing PIGR alone or PIGR with secretory cell markers SCGB1A1 and/or SCGB3A2 (n = 10,908 cells (4,571 PIGR expressing) from 17 airways in 6 deceased lung donors without chronic respiratory disease. (E) Immunostaining for pIgR (red), Scgb1a1 (green, right panel), or FoxJ1 (green, left panel) in large and small airways from deceased lung donors without chronic respiratory disease. Scale bar = 50 μm. Inserts 2X magnification.

Figure 2. PIGR is primarily expressed by secretory cells in fresh human lung tissue. (A) Tissue processing workflow for single-cell RNA sequencing experiments. (B) UMAP-embedded image showing cell clusters derived from non-biased, graph-based clustering of EPCAM+ cells derived from the distal lungs of COPD and control patients. (C) UMAP-embedded showing integration of cells according to clinical status. (D) Violin plots show PIGR expression in COPD explants and organ donors without known chronic respiratory disease (e.g. controls). The height of each violin corresponds to the degree of expression/cell and the width of the violin corresponds to the
number of expressing cells for a given level of expression. * = p < 0.001; ** = p < 0.0001 (negative binomial regression).

**Figure 3.** plgR is expressed primarily by secretory cells in murine airways. (A) Immunostaining for plgR (red), the ciliated cell marker alpha tubulin (white), and the secretory cell marker Scgb1a1 (green) in airways from wild-type C57BL6/J mice. DAPI staining of nuclei (DNA) is shown in blue. Scale bar = 20 µm. (B) Diagram describing methods utilized for DAPT-T treatment in primary murine tracheal epithelial cells (MTECs). (C) Immunoblotting for plgR in ALI-differentiated MTECs with and without addition of the gamma-secretase inhibitor DAP-T, which restricts secretory cell differentiation (n = 3 inserts/group). β-actin is included as a loading control and acetylated α-tubulin is included to show DAP-T did not affect ciliated cell differentiation. (D) Quantification of (C) by densitometry. All three bands of plgR are included in the densitometry analysis. plgR expression normalized across samples using β-actin. * = p < 0.01 (t-test).

**Figure 4.** Ciliated cell-derived plgR is dispensible for protection against emphysema. (A,B) Immunostaining for plgR and GFP in adult plgR\textsuperscript{Aciliated} and plgR\textsuperscript{Aclub} mice. White arrows in (A) highlight plgR\textsuperscript{+}GFP\textsuperscript{−} cells in plgR\textsuperscript{Aciliated} mice. Scale bars = 50µm. (C) Low-magnification images (10x) of the lung parenchyma in 6-month-old Cre\textsuperscript{−} and Cre\textsuperscript{+} plgR\textsuperscript{Aciliated} mice shows absence of emphysema in both strains (H&E). (D) Quantification of emphysema (by mean linear intercept, MLI) in 6-month-old C57Bl6 WT and Cre\textsuperscript{+} and Cre\textsuperscript{−} plgR\textsuperscript{Aciliated} mice (n = 4-7 mice/group). Box-and-whisker plots represent median, interquartile range, and range. Results are not significant (ANOVA).

**Figure 5.** Loss of club cells does not explain loss of SIgA in COPD airways. (A) Percentage of \textit{SCGB1AI}\textsuperscript{+} or \textit{SCGB3A2}\textsuperscript{+} cells per airway among DAPI\textsuperscript{+} cells as assessed by RNA-ISH in
control lungs \((n = 6, 17\) airways\) vs COPD \((n = 6, 18\) airways\). \((B)\) Representative images of a SIgA\(^+\) and SIgA\(^-\) small airways (based on IgA immunostaining) from the explanted lungs of a COPD patient. White arrows point to epithelial surface. Scale bars = 100 \(\mu\)m , inserts 2X magnification. \((C)\) Percentage of \(SCGB1A1^+\) or \(SCGB3A2^+\) cells per airway among DAPI\(^+\) cells as assessed by RNA-ISH in SIgA\(^+\) and SIgA\(^-\) airways as shown in \((B)\). \((D)\) Intensity of pIgR staining per pIgR positive cells in SIgA\(^+\) or SIgA\(^-\) airways as determined by HALO analysis. \((E)\) Percentage of pIgR\(^+\) cells among DAPI\(^+\) cells in SIgA\(^+\) versus SIgA\(^-\) airways as determined by HALO analysis. \((D,E)\) \(p =\) not significant (ns); (Mann-Whitney test). \((F)\) IgA and pIgR staining on serial sections of two different SIgA negative airways showing high (left) or low pIgR expression. Scale bars = 100 \(\mu\)m.

**Figure 6.** Human SIgA is degraded by bacterial and host proteases *in vitro*. \((A)\) SIgA was incubated with conditioned media from NTHi strain 1479 for 24 hours then assessed for degradation/cleavage products in the IgA heavy chain (top panel) or in the secretory component (bottom panel). PBS and non-inoculated media were used as negative controls. \((B)\) Quantification of full length IgA heavy chain from the top panel of A. \((C)\) Quantification of full length secretory component from the bottom panel of A. \((D)\) SIgA was incubated with human neutrophil elastase (HNE) for 24 hours then assessed for degradation/cleavage products in the IgA heavy chain (top panel) or in the secretory component (bottom panel). The buffer used to dissolve the HNE (vehicle) was used as a negative control. A non-specific mammalian protease inhibitor was also incubated with SIgA and HNE as a control. \((E)\) Quantification of full length IgA heavy chain from the top panel of D. \((F)\) Quantification of full length secretory component from the bottom panel of D. \(* = p < 0.01\) \((t\)-test\).
Online Supplemental Figure Legends

Supplemental Figure 1. Example of region of interest definition and masking using HALO image analysis software. Images of a small airway from a non-diseased donor with and without masking performed using HALO. The region of interest was defined as shown by the yellow line and was drawn at the base of the airway epithelium.

Supplemental Figure 2. Canonical markers used to define cell types in the merged control and COPD dataset. Violin plots showing expression of markers used in manual annotation across cell types. The height of each violin corresponds to the degree of expression/cell and the width of the violin corresponds to the number of expressing cells for a given level of expression.

Supplemental Figure 3. Construction of the plgR\textsuperscript{A\textsubscript{ciliated}} and plgR\textsuperscript{A\textsubscript{club}} mouse lines and tamoxifen administration schedule for plgR\textsuperscript{A\textsubscript{club}} mice. (A) Design of the flox-plgR mouse model. Schematic showing the plgR gene region in wild-type C57BL6/J, flox-targeted, and neomycin-deleted flox-plgR mice. LoxP sites flank exons 3 through 11 of plgR. The coding regions for GFP are split between the upstream and downstream loxP sites such that Cre-mediated recombination results in GFP expression. FRT sites were used to remove the neomycin selection cassette; after neomycin deletion one 143 bp FRT site remains. The 5’ and 3’ regions outside of the targeting vector are shown in red and blue, respectively. (B) Diagram depicting generation of plgR\textsuperscript{A\textsubscript{ciliated}} and plgR\textsuperscript{A\textsubscript{club}} mice by breeding flox-plgR mice with FoxJ1.Cre and Scgb1a1.CreERT2 mice, respectively. (C) Schematic showing the timing of tamoxifen administration in plgR\textsuperscript{A\textsubscript{club}} mice. Tamoxifen chow was alternated with regular chow at weekly intervals to minimize toxicity.

Supplemental Figure 4. plgR\textsuperscript{A\textsubscript{club}} mice have lower plgR expression than plgR\textsuperscript{A\textsubscript{ciliated}} or Cre\textsuperscript{−} littermate controls. (A, B) Representative low-power tiled images from an adult plgR\textsuperscript{A\textsubscript{ciliated}} and plgR\textsuperscript{A\textsubscript{club}} mouse showing plgR and GFP staining in both lines. Identical camera settings were
used for both images. (C) Immunoblotting for pIgR in whole-lung lysates from wild-type C57BL6/J, pIgR\(^{\Delta\text{ciliated}}\), pIgR\(^{\Delta\text{club}}\) mice and Cre\(^{-}\) littermate controls as indicated. β-actin is included as a loading control. (D) Densitometry-based measurement of pIgR expression in pIgR\(^{\Delta\text{ciliated}}\) and pIgR\(^{\Delta\text{club}}\) mice and Cre\(^{-}\) littermate controls.
References


Figure 1.

A) Serial sections from pig terminal bronchioles stained for PIGR, SCGB1A1 and FOXJ1. Scale bar, 50 μm.

B) Bar graphs showing FOXJ1 and PIGR + SCGB1A1+ median expression for each group. The error bars represent ± SEM. *p < 0.05 compared to all other groups.

C) Serial sections from pig terminal bronchioles stained for PIGR, SCGB1A1, SCGB3A2 and DAPI.

D) Bar graph showing the percentage of cells expressing PIGR, SCGB1A1 and SCGB3A2 in the small and large airways.

E) Serial sections from pig terminal bronchioles stained for plgR, FoxJ1 and DAPI, and plgR, Scgb1a1 and DAPI.
Figure 2.

A. Organ donors, n=10
   3 TGen, 7 VUMC
   COPD explants, n=11
   3 TGen, 8 VUMC

B. AT1
   AT2
   Basal
   Ciliated
   KRT5-KRT17+
   Proliferating AT2
   Secretory - SCGB1A1+/SCGB3A2+
   Secretory - SCGB1A1+
   Secretory - SCGB3A1+
   Secretory - SCGB3A2+
   Transitional

C. Control, n=8,395 cells
   COPD, n=14,680 cells

D. PIGR

Expression Level

Control COPD
Figure 3.

A) Immunofluorescence images showing localization of \( \alpha \)-tubulin, plgR, and DAPI. Three panels depict different markers: Scgb1a1, plgR, and DAPI. Scale bars: 20 \( \mu \)m.

B) Schematic diagram illustrating the experimental workflow: C57B16/J WT mice → Tracheas removed and tracheal epithelial cells isolated → MTECs expanded in submerged culture → DAPT or vehicle (DMSO) added during terminal differentiation.

C) Western blot analysis showing intact plgR and SC at 125 kDa and 90 kDa, \( \beta \)-actin as a loading control, and \( \alpha \)-tubulin.

D) Graph depicting plgR (A.U.) levels in Control and DAPT conditions. * indicates statistical significance. 

Available under a Creative Commons Attribution Non-commercial No-derivatives 4.0 International license (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a Creative Commons license and a detailed description is provided in the preprint.

https://doi.org/10.1101/2021.11.10.467794
doi: bioRxiv preprint
Figure 4.

A. Illustration of plgR^ciliated Cre^- and plgR^ciliated Cre^+ cells with GFP and DAPI staining.

B. Illustration of plgR^club Cre^-/tamoxifen and plgR^club Cre^+/tamoxifen cells with GFP and DAPI staining.

C. Staining of Cre^- and Cre^+ cells with plgR^ciliated.

D. Graph showing mean linear intercept (Lm) with no significant difference (ns) between WT, plgR^ciliated Cre^-, and plgR^ciliated Cre^+ groups.
Figure 5.

(A) IgA expression in pIgR+ cells

(B) SCGB1A1+ SCGB3A2+ cells

(C) IgA+ IgA- cells

(D) pIgR expression in pIgR+ cells

(E) % of total cells

(F) IgA DAPI, plgR DAPI, IgA DAPI, plgR DAPI
Supplemental Figure 1.

Unedited

Masked
Supplemental Figure 3.

(A) WT

(B) FoxJ1.Cre × Scgb1a1.CreERT2 → plgR<sup>Wt</sup> × plgR<sup>Wt</sup> → plgR<sup>Δclub</sup>

(C) Born → Tamoxifen on → on → on → on → on → Euthanasia on

2-5 mo. old → 1 week → 5-8 mo. old
Supplemental Figure 4.

(A) Intact plgR

(B) plgR^\Delta{ciliated}

(C) Western blot analysis of plgR and SC proteins. 
- 125 kDa
- 90 kDa
- \beta-actin

(D) Quantification of plgR expression:
- ns
- *